RNA

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021

Friday, October 15, 2021 - 9:05pm

SEATTLE, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at ASN Kidney Week 2021 from November 4-7, 2021. The six abstracts covering the BION-1301 and atrasentan clinical programs will be delivered as ePoster presentations.

Key Points: 
  • For more information on these and other abstracts, please visit the ASN Kidney Week 2021 website and Abstract Supplement .
  • To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinooks website.
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • Chinooks product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease

Friday, October 15, 2021 - 3:21pm

Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that manufacturing has commenced of MLR-1019 (armesocarb) for use in the Company’s planned Phase 2a clinical trial as a new therapeutic for Parkinson’s disease (PD). Adhera is also pleased to inform shareholders that a new patent has been issued covering MLR-1019 in Korea.

Key Points: 
  • To the best of the Companys knowledge, all existing agents that treat movement disorder, exacerbate non-movement disorder features of PD.
  • Enrollment in the Phase 2 trial is expected to consist of Parkinsons disease patients with L-DOPA induced dyskinesia, a commonly seen and potentially disabling movement side effect of treating PD with levodopa.
  • Product manufacturing is a milestone for us as we move closer to initiating what we believe could be a landmark study in Parkinsons disease treatments, commented Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics.
  • MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021

Friday, October 15, 2021 - 1:30pm

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place virtually from November 12-15, 2021.

Key Points: 
  • SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place virtually from November 12-15, 2021.
  • A third poster presentation will focus on the impact of chronic HBV and its treatments on patients lives, as well as the perceived value of a functional cure.
  • Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

Friday, October 15, 2021 - 2:00pm

LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern time has been set for Khursheed Anwer, Ph.D., executive vice president and chief science officer, to deliver his presentation at the International Vaccines Congress. A link to Dr. Anwer’s presentation, titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems,” will be available on Celsion’s website at that time and can be viewed here.

Key Points: 
  • PLACCINE is Celsions proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines.
  • An adaptation of the Companys TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions.
  • Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.
  • Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

Friday, October 15, 2021 - 12:00pm

Hansoh Pharma is supported by over 12,000 dedicated employees in China and the United States.

Key Points: 
  • Hansoh Pharma is supported by over 12,000 dedicated employees in China and the United States.
  • Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.
  • Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.

Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River

Friday, October 15, 2021 - 6:00am

Further investment and expansion of the facility and its current 128 employee roster is expected to begin immediately.

Key Points: 
  • Further investment and expansion of the facility and its current 128 employee roster is expected to begin immediately.
  • This acquisition is a major investment for us and fits well with Fleries strategy of investing in the gene and cell therapy space in Europe and the US, said Thomas Eldered, President of Flerie Invest.
  • Flerie Invest is a biotech and pharma investor managing a portfolio of more than 16 companies in Sweden, UK, US, the Netherlands, Iceland and Israel.
  • Flerie Invest, with offices in Stockholm and London, is an active member of SwedenBIO and the British Venture Capital Association (BVCA).

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

Thursday, October 14, 2021 - 9:54pm

Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.

Key Points: 
  • Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.
  • An estimated 10% or more of adults with AAT deficiency develop clinically meaningful liver disease.2,3 People with AAT deficiency may also develop lung disease, including emphysema.
  • Dicerna is currently investigating the use of belcesiran for the treatment of AATLD in the SHINE clinical development program.
  • The Liver Meeting is a registered trademark of the American Association for the Study of Liver Diseases.

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Thursday, October 14, 2021 - 6:35pm

Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.

Key Points: 
  • Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.
  • The companys flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.
  • Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services.
  • The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery.

Imec signs licensing agreement with miDiagnostics to commercialize its patented technology for fast and reliable COVID-19 diagnosis based on exhaled breath

Thursday, October 14, 2021 - 4:39pm

"I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.

Key Points: 
  • "I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.
  • "We have succeeded in transforming a promising concept and groundbreaking technology into a functional proof-of-concept that has passed both user tests and clinical studies.
  • This is the first time that we have gone this far in the development of our chip technology towards commercialization.
  • The license agreement with miDiagnostics is an important milestone for imec: Our breakthrough technology will help curb the COVID-19 pandemic in the foreseeable future."

Versatope Expands Scientific Advisory Board with Dr. Drew Weissman and Board of Directors with Dr. James Kuo and Jeremy Gowler

Thursday, October 14, 2021 - 3:18pm

LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.

Key Points: 
  • LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.
  • Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.
  • Versatope is developing first-in-class vaccines and immuno-therapeutics for infectious and chronic diseases by using their proprietary recombinant outer membrane vesicle (rOMV) platform.
  • Dr. Drew Weissman, MD, PhD,is the Roberts Family Professor of Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania.